With support from VCRO’s expert team, a client’s Phase II clinical trial of universal allogeneic chimeric antigen receptor T-cell (UCAR-T) therapy for brain metastases from advanced solid tumors has received U.S. FDA authorization to proceed in October 2026. VCRO supported the clinical development strategy, trial design, and integration of regulatory materials and communications.
Since 2008, VCRO has been active in the cell therapy field, building extensive experience in the clinical development of cell and regenerative medicine products. To date, the company has supported more than 57 related projects. From early development strategy and trial design to regulatory submissions, communications with regulatory authorities, and the launch and execution of multinational clinical trials, VCRO offers comprehensive, end-to-end services. Our experience helps clients navigate regulatory and operational hurdles and move their products toward the next key milestone.
If you are planning clinical development in Taiwan or the United States for cell therapies, regenerative medicine, advanced therapies, or other innovative medicines, please submit an inquiry through the VCRO website to contact our expert team. We look forward to working with you to develop the right product development and international clinical strategy for your needs.
